Lutathera ® : The First FDA- and EMA-Approved Radiopharmaceutical for Peptide Receptor Radionuclide...
Lutathera ® : The First FDA- and EMA-Approved Radiopharmaceutical for Peptide Receptor Radionuclide Therapy
About this item
Full title
Author / Creator
Publisher
Switzerland: MDPI AG
Journal title
Language
English
Formats
Publication information
Publisher
Switzerland: MDPI AG
Subjects
More information
Scope and Contents
Contents
As the first radiopharmaceutical for Peptide Receptor Radionuclide Therapy (PRRT), Lutathera
was approved by the EMA in 2017 and the FDA in 2018 for the treatment of somatostatin receptor (SSTR) positive gastroenteropancreatic neuroendocrine tumors. Using the concept of PRRT, Lutathera
combines the radionuclide
Lu with the somatostatin ana...
Alternative Titles
Full title
Lutathera ® : The First FDA- and EMA-Approved Radiopharmaceutical for Peptide Receptor Radionuclide Therapy
Authors, Artists and Contributors
Author / Creator
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_doaj_primary_oai_doaj_org_article_1a0bd205f21540e7b1cbd5c910755766
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_doaj_primary_oai_doaj_org_article_1a0bd205f21540e7b1cbd5c910755766
Other Identifiers
ISSN
1424-8247
E-ISSN
1424-8247
DOI
10.3390/ph12030114
